We use science to save lives, and so can you. We are currently recruiting for Scientist II's to join the ADQC. The purpose of this role is to perform and report laboratory-based experiments, in accordance with scientific or regulatory requirements. Our AD&QC team supports the development of products through analytical testing to facilitate manufacturing, shelf life setting and process development, ensuring appropriate quality controls and use of analytics. We have opportunities within our: Darwin team who performs lab-based analytical assays (PCR, ELISA, Tissue culture, and Gel electrophoresis) to provide analytical support for QC batch release as well as development and investigational and our: Curie team who performs lab-based analytical assays (PCR, Tissue culture, performed in Containment Level 3 Laboratories) to provide analytical support for QC batch release as well as development and investigational. Your responsibilities in this role would be: • Perform analytical testing as part of QC release and stability. • Timely and accurate completion of GxP paperwork. • Familiar with the principles of experimental design and implementation. • Flagging process improvement to management • Identifying non-conformances (OOS, OOE, CC) and completion under supervision. • Will report to the Group Leader or his/her delegated Grade 5 to 6 Scientist. • Personally responsible for the completion of tasks in relation to their criticality. • Joint responsibility for maintenance and compliance of a GxP laboratory area and GxP “housekeeping” procedures. • Work will be conducted in accordance with the OXB Quality Management system. • High regard for safety and display a high level of good laboratory citizenship. We are looking for: • Educated to a minimum of BSc Degree in a relevant discipline, or basic experience of working in a related environment. • Some demonstrable competencies in performing laboratory tasks and general experimental procedures. • Understanding of laboratory health and safety requirements. • Computer Literacy with MS Word, Excel & Outlook & Teams. • Some appreciation of Laboratory Information Management Systems (LIMS) • Understanding of regulatory requirements e.g. GMP, GLP, GCP and/or Validation and Quality Management systems. • Some familiarity with the regulatory requirements for analytical work (e.g. product specifications, stability testing guidelines etc). • Highly motivated and enthusiastic. • Ability to work well in a team. About Us: OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXB’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise. What’s in it for you: • Highly competitive total reward packages • Wellbeing programmes • Development opportunities • Welcoming, friendly, supportive colleagues • A diverse and inclusive working environment • Our values are: Responsible, Responsive, Resilient, Respect • State of the art laboratory and manufacturing facilities We want you to feel inspired every day. We’re future-focused and our business is growing rapidly. We succeed together through passion, commitment and teamwork, and so can you. Collaborate. Contribute. Change lives Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.